Immune Checkpoint-Related Gene Prognostic Signature Characterizes the Immunosuppressive Microenvironment and Predicts Immunotherapy Response in Clear Cell Renal Cell Carcinoma
- 1Department of Urology, Kidney and Urology, Pelvic Floor Disorder Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen 518107, China
- 2Department of Anesthesiology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen 518107, China
- 3Department of Urology, The Affiliated Huizhou Hospital, Guangzhou Medical University, Huizhou 516002, China
Abstract
Clear cell renal cell carcinoma (ccRCC) shows heterogeneous responses to immune checkpoint inhibitors (ICIs). We aimed to develop an immune checkpoint-related gene (ICRG) signature for risk stratification, tumor microenvironment characterization, and immunotherapy prediction. Transcriptomic and clinical data from two independent ccRCC cohorts were used for consensus clustering and construction of a prognostic ICRG signature via LASSO and Cox regression, validated internally and externally. Tumor microenvironment and immunotherapy response were assessed using ESTIMATE, ssGSEA, TIDE, and the IMmotion150 trial. LIPA function was tested in vitro. A four-gene signature (SIGLEC8, TNFSF13B, C1S, LIPA) stratified patients into high- and low-risk groups with significantly different overall survival (p < 0.001) and consistent 5-year AUC of 0.70–0.78. High-risk patients displayed an immunosuppressive microenvironment with T-cell exhaustion and upregulated checkpoints. Risk score correlated with reduced benefit from combined immunotherapy and targeted therapy (p < 0.01) and shorter progression-free survival (p = 0.0035). LIPA overexpression suppressed proliferation, migration, and invasion in CAKI-1 and CAKI-2 renal carcinoma cells. This ICRG signature serves as a potential prognostic biomarker and may aid in predicting immunotherapy response. Furthermore, LIPA showed tumor-suppressive potential, providing a rationale for future personalized treatment strategies.
Related
- Sphingolipid metabolic subtyping defines SPHK1 as an oncogene and characterizes immunosuppressive TME features in gastric cancer.
- Computer-Aided Drug Design for Immunosuppressive Tumor Microenvironment Reprogramming: A Critical Review
- ANGPT2 promotes angiogenesis and immunosuppressive microenvironment in colorectal cancer.
- Extracellular targeted protein degradation for tumor immune microenvironment reprogramming: from checkpoint blockade to checkpoint elimination
- Antimicrobial Resistance and Infectious Complications in Cancer Immunotherapy: CAR-T Cells, Bispecific Antibodies and Immune Checkpoint Inhibitors
BibTeX
@article{dai2026immune,
title = {{Immune Checkpoint-Related Gene Prognostic Signature Characterizes the Immunosuppressive Microenvironment and Predicts Immunotherapy Response in Clear Cell Renal Cell Carcinoma}},
author = {Lei Dai and Lei Zheng and Hao Yuan and Jun Li and Jun Pang and Feng Yue},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = nov,
doi = {10.3390/ijms272210115},
url = {https://www.mdpi.com/1422-0067/27/22/10115},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Immune Checkpoint-Related Gene Prognostic Signature Characterizes the Immunosuppressive Microenvironment and Predicts Immunotherapy Response in Clear Cell Renal Cell Carcinoma
AU - Lei Dai
AU - Lei Zheng
AU - Hao Yuan
AU - Jun Li
AU - Jun Pang
AU - Feng Yue
PY - 2026
DA - 2026/11/11
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms272210115
UR - https://www.mdpi.com/1422-0067/27/22/10115
AB - Clear cell renal cell carcinoma (ccRCC) shows heterogeneous responses to immune checkpoint inhibitors (ICIs). We aimed to develop an immune checkpoint-related gene (ICRG) signature for risk stratification, tumor microenvironment characterization, and immunotherapy prediction. Transcriptomic and clinical data from two independent ccRCC cohorts were used for consensus clustering and construction of a prognostic ICRG signature via LASSO and Cox regression, validated internally and externally. Tumor microenvironment and immunotherapy response were assessed using ESTIMATE, ssGSEA, TIDE, and the IMmotion150 trial. LIPA function was tested in vitro. A four-gene signature (SIGLEC8, TNFSF13B, C1S, LIPA) stratified patients into high- and low-risk groups with significantly different overall survival (p < 0.001) and consistent 5-year AUC of 0.70–0.78. High-risk patients displayed an immunosuppressive microenvironment with T-cell exhaustion and upregulated checkpoints. Risk score correlated with reduced benefit from combined immunotherapy and targeted therapy (p < 0.01) and shorter progression-free survival (p = 0.0035). LIPA overexpression suppressed proliferation, migration, and invasion in CAKI-1 and CAKI-2 renal carcinoma cells. This ICRG signature serves as a potential prognostic biomarker and may aid in predicting immunotherapy response. Furthermore, LIPA showed tumor-suppressive potential, providing a rationale for future personalized treatment strategies.
SN - 1422-0067
ER -